Precision Medicine in Oncology®

Dr. Mark Kris from Memorial Sloan-Kettering Cancer Center Discusses the Pemetrexed Clincal Trial Results

Vismodegib has demonstrated positive overall response rates in patients with advanced basal cell carcinoma.

Patients with basal cell carcinoma had an eightfold decrease in lesion area when treated with GDC-0449

During the past 20 years, disease management systems have mushroomed in medicine

Both industry and clinical sources agree that cancer vaccine research is finally on the right track to achieve major advances in treatment.

The investigators developed a computer tool that is dramatically better for finding genetic missteps that promote cancer.

Dr Paz-Ares from Seville University Hospital Discusses Pemetrexed Clinical Trial

Currently, more than 250 physicians and scientists work in concert to provide state-of- the art diagnosis, treatment, and aftercare for the more than 20,000 patients seen each year at the UW hospitals, clinics, and affiliate clinical facilities

Dr. Chapman From Memorial Sloan-Kettering Describes the Vemurafenib Clinical Trial

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib Trial Design

Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores

Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes

As a child Joyce Ann O'Shaughnessy enjoyed science and her home chemistry set. Still, she didn't give much thought to pursuing the subject beyond the confines of her school - until she faced a tragedy.

An experimental melanoma vaccine gp100 peptide vaccine in combination with IL2 may shrink tumors and prevent the progression of late-stage melanoma

The mammalian target of rapamycin (mTOR) is a master switch, central regulator, or key integrator of cell growth and proliferation

Highlights on updates to the clinical practice guidelines from the annual National Comprehensive Cancer Network (NCCN) conference

Oncologist James Berenson, MD, likes all of his patients, especially the ones with whom he skis.

Donna Berry from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the Future of Oncology Nursing

The past decade has brought a significant increase in attention to the role that food and nutrients might play in fighting cancer.

Links to resource from across the web for brain cancer; includes news briefs, patient education, research and clinical trials

Cabozantinib (XL184), an investigational oral tyrosine kinase inhibitor, demonstrated antitumor activity in multiple types of advanced solid tumors.

Dr. Pecora on the Pathway Inhibitor Cabozantinib (XL184)

Jane Armer the director of ALFP on Findings From Her Lymphedema Research

As cancer-fighting therapies become more targeted, clinicians are looking increasingly toward emerging technologies to help confirm the primary site of a patient's disease.

Michael T. Lewis, PhD, runs a research lab at the Baylor College of Medicine focused on understanding the role of hedgehog signaling in mammary gland development and breast cancer